Field Notes — September 23, 2026

GM Shipped Patriot Interceptor Parts in 22 Days. Lockheed Is Buying the Rate.

All Field Notes
September 23, 2026 Defense Hardware

Lockheed Martin signed a production contract with GM Defense on August 6. Twenty-two days later, the first batch of GM-made housings for the PAC-3 MSE arrived. The PAC-3 MSE is the interceptor a Patriot battery fires. Tim Cahill, who runs Lockheed's missiles business, called the turnaround extraordinary, and Defense News noted that parts like these traditionally take months or years. The announcement leaves out three things: how many housings were in the shipment, whether they have passed qualification, and how many GM can make in a month. Those three blanks are what Lockheed is short of.

A date is one delivery

The easy read is that a car company just outran the defense industrial base. But a first shipment proves only that GM can cast and machine a housing to a drawing, and GM has been casting and machining metal at automotive volume for generations, so that was never much in doubt. An interceptor line needs something harder from a supplier: the same part, to the same spec, every week, with the records that let it fly. A date is one delivery. A rate is a business.

The Pentagon's own paper trail says the rate is the scarce thing. On August 5, Deputy Defense Secretary Steve Feinberg asked defense companies for "significantly faster, more aggressive delivery schedules" on 16 critical programs. PAC-3 MSE and THAAD were on the list, and the deadline was August 26. Defense News reported on September 21 that the Pentagon still hasn't said how many companies replied or what schedules they offered. The Center for Strategic and International Studies estimates production takes about 42 months for a PAC-3 MSE interceptor and 53 for a THAAD round.

Set 22 days against 42 months. The first box doesn't move the 42 months unless the housings keep coming every month and every lot passes inspection. Lockheed is spending $8 billion to $9 billion to expand munitions production across more than 20 U.S. sites. That money builds Lockheed's own plants, and the plants still wait on parts from suppliers like GM.

What a prime is buying from you

Speed to first article is the number you control as a supplier, and it demos well. A prime's supply chain team wants two other answers from you: what rate you'll commit to hold, and how long until your part is qualified to go into the product. Those two answers decide whether you're a line item in their production plan or a pilot they talk about at a conference.

GM sits on the other side of that table every day. A new part goes into a GM vehicle after a production run shows the process can make it, again and again, inside tolerance. A prototype that fits is where that approval starts. GM Defense is now being judged by the kind of rule its parent company has applied to its own suppliers for decades. A battery pack startup courting an automaker meets that approval process before it gets to negotiate price. A contract manufacturer quoting a medical device company meets its version in process validation.

Whatever your vertical, you need to know what your version of that production run looks like, and you need to show it before the buyer asks. It's built from fixture design, incoming material inspection, the second shift, and a yield number over 30 days instead of three. A prime checks each of those before it puts your part on a schedule.

Dave's take

If you sell parts to a prime, put the monthly rate you'll commit to hold on your first slide and your qualification schedule on the second slide, and move the first-article date to the appendix. Lockheed has told us when the first box arrived. The announcement I'd want to read says how many housings GM ships in March.

From Dave’s video library

Dave makes the case against vanity dashboards and names the five numbers worth tracking instead.

Dave Saunders

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for product companies. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →